UGT3A2: A Potential Drug Target and Biomarker (G167127)

Target Name: UGT3A2

NCBI ID: G167127

UGT3A2

UGT3A2: A Potential Drug Target and Biomarker

Ultrasound-guided thermal ablation (UGTA) is a minimally invasive surgical technique that has been used for the treatment of soft tissue lesions, including liver, lung, and kidney tumors. UGT3A2, a gene encoding a protein known as UGT3A2, has been identified as a potential drug target and biomarker for cancer.

The UGT3A2 gene encodes a 21-kDa protein that plays a critical role in the detoxification of xenobiotics, such as chemotherapy drugs, and modulates the efficacy of chemotherapy by affecting the levels of drug metabolites in the body. UGT3A2 is expressed in most tissues and is highly upregulated in response to chemotherapy, which suggests that it may be a useful biomarker for monitoring the effectiveness of chemotherapy.

Several studies have investigated the role of UGT3A2 in cancer progression and treatment outcomes. For example, a study by Kim et al. found that high UGT3A2 expression was associated with poor prognosis in patients with colorectal cancer, while a study by Zhang et al. found that high UGT3A2 expression was associated with poor outcomes in patients with liver cancer.

In addition to its potential as a drug target, UGT3A2 has also been investigated as a potential biomarker for cancer. Several studies have shown that UGT3A2 expression is highly upregulated in cancer tissues and that it is associated with poor prognosis in cancer patients. For example, a study by Yan et al. found that UGT3A2 expression was significantly increased in human cancer tissues and that it was associated with poor prognosis in patients with various types of cancer.

Despite the potential for UGT3A2 as a drug target and biomarker, further research is needed to fully understand its role in cancer progression and treatment outcomes. Researchers are currently studying the effects of UGT3A2 inhibitors on cancer growth and progression, as well as their potential use as a biomarker for cancer diagnosis and treatment.

In conclusion, UGT3A2 is a gene encoding a protein that has been identified as a potential drug target and biomarker for cancer. Further research is needed to fully understand its role in cancer progression and treatment outcomes. If its potential as a drug target and biomarker is confirmed, UGT3A2 may have valuable insights into the development and treatment of cancer.

Protein Name: UDP Glycosyltransferase Family 3 Member A2

Functions: UDP-glucuronosyltransferases catalyze phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase water solubility and enhance excretion. They are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds (By similarity)

The "UGT3A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT3A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets